Quantcast
Last updated on April 16, 2014 at 5:49 EDT

Latest ViroPharma Incorporated Stories

2011-11-02 11:00:00

EXTON, Pa., Nov. 2, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, president and chief executive officer of ViroPharma, will present at the Lazard Capital Markets 8th Annual Healthcare Conference at 1:30 P.M. ET on Wednesday, November 16, 2011. The conference is being held at the Pierre Hotel in New York City. Charles Rowland, vice president and chief financial officer, of ViroPharma, will present at the Piper Jaffray 23rd Annual...

2011-10-27 06:05:00

EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the third quarter ended September 30, 2011. In the third quarter of 2011, we: Achieved a record $143 million in net product sales, representing 21 percent growth over the third quarter of 2010; Recorded $65 million in net sales of Cinryze for the third quarter and $184 million for the 9 month period, representing Cinryze growth of 33 percent and 48 percent...

2011-10-27 06:00:00

EXTON, Pa., Oct. 27, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced that it has signed a definitive agreement to acquire DuoCort Pharma AB, a private company based in Helsingborg, Sweden focused on improving glucocorticoid replacement therapy. The acquisition of DuoCort Pharma AB will further expand ViroPharma's orphan disease commercial product pipeline. The company intends to discuss this acquisition on its third quarter financial results conference call...

2011-10-19 11:00:00

EXTON, Pa., Oct. 19, 2011 /PRNewswire/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2011 are expected to be released on Thursday, October 27, 2011 before the open of the U.S. financial markets. The company will host a conference call and live audio webcast at 8:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the 2011 third quarter financial results and other business. The press release and the live...

2011-09-30 07:00:00

EXTON, Pa., Sept. 30, 2011 /PRNewswire/ -- ViroPharma Incorporated (NASDAQ: VPHM) today announced the license of worldwide rights from Intellect Neurosciences, Inc. (OTCBB: ILNS) to its clinical stage drug candidate, OX1, being developed for the treatment of Friedreich's Ataxia (FA), a rare, hereditary, progressive neurodegenerative disease. OX1, or indole-3-propionic acid (IPA), is a naturally occurring, small molecule that has potent anti-oxidant properties that can protect against...

2011-09-15 06:30:00

EXTON, Pa., Sept. 15, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the company's Board of Directors has authorized the use of up to an additional $200 million to repurchase shares of its common stock and/or its 2% Senior Convertible Notes due 2017. The company also announced that it has substantially completed the $150 million securities repurchase announced in March 2011. "We remain committed to maximizing shareholder value, and this expanded stock...

2011-09-13 14:00:00

EXTON, Pa., Sept. 13, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) and Halozyme Therapeutics (Nasdaq: HALO) announced today that ViroPharma has initiated an open-label, multi-dose Phase 2 study to evaluate the safety, and pharmacokinetics and pharmacodynamics of subcutaneous administration of Cinryze® (C1 esterase inhibitor [human)] in combination with Halozyme's Enhanze(TM) technology, a proprietary drug delivery platform using Halozyme's recombinant human...

2011-09-06 08:25:00

EXTON, Pa., Sept. 6, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that the European Commission has granted a Centralized Pediatric Use Marketing Authorization (PUMA) for Buccolam® (midazolam, oromucosal solution), for treatment of prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, from 3 months to less than 18 years of age. This action by the European Commission represents the first product approval...

2011-08-31 11:00:00

EXTON, Pa., Aug. 31, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that William C. Roberts, ViroPharma's Vice President of Corporate Communications, will present at the Stifel Nicolaus 2011 Healthcare Conference at 1:30 P.M. ET on Wednesday, September 7, 2011. The conference is being held in Boston. ViroPharma's presentations will be webcast live for investors through www.viropharma.com and available for a period of 14 days following the conferences. About...

2011-07-28 06:30:00

EXTON, Pa., July 28, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) reported today its financial results for the second quarter ended June 30, 2011. In the second quarter of 2011, we: Achieved a record $129 million in net product sales, including $62.5 million in net sales of Cinryze® (C1 esterase inhibitor [human]) representing Cinryze growth of 55 percent over the same period in 2010; Realized non-GAAP adjusted net income of $36 million; GAAP net income...